Status:
COMPLETED
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Psoriasis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chr...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with chronic plaque psoriasis covering at least 3% of body surface area. Female subjects must be postmenopausal or surgically sterilized.
- Exclusion criteria:
- Recent use of biologic agents, oral psoriasis medications or phototherapy
Exclusion
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00848055
Start Date
December 1 2008
Last Update
November 1 2013
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
1240.1.05 Boehringer Ingelheim Investigational Site
Boise, Idaho, United States
2
1240.1.06 Boehringer Ingelheim Investigational Site
Evansville, Indiana, United States
3
1240.1.04 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
4
1240.1.02 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States